Mirum Pharmaceuticals, Inc. MIRM Volixibat — Payments for achievement of various milestones
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:PaymentsForAchievementOfVariousClinicalDevelopmentRegulatoryAndCommercialMilestones.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:28 PM EST
- Fiscal year
- FY2025
- Accession
- 0001759425-26-000013
The Company is obligated to pay Shire up to an aggregate of $109.5 million upon the achievement of certain clinical development and regulatory milestones for Livmarli in certain indications and an additional $25.0 million upon regulatory approval of Livmarli for each and every other indication. In addition, the Company is required to pay up to an aggregate of $30.0 million upon the achievement of certain clinical development and regulatory milestones for volixibat solely for the first indication sought. Upon commercialization, the Company is obligated to pay Shire commercial milestones on total licensed products up to an aggregate of $30.0 million. Through December 31, 2025 under this agreement, the Company paid or accrued $101.5 million for the achievement of various clinical development, regulatory and commercial milestones.
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Mirum Pharmaceuticals, Inc.'s volixibat — payments for achievement of various milestones?
- Mirum Pharmaceuticals, Inc. (MIRM) reported volixibat — payments for achievement of various milestones of $25.38M in Q4 2025.
- How has Mirum Pharmaceuticals, Inc.'s volixibat — payments for achievement of various milestones changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s volixibat — payments for achievement of various milestones increased by 17.3% year-over-year, from $21.63M to $25.38M.
- What does volixibat — payments for achievement of various milestones mean?
- Reflects the actual cash outflows disbursed to third parties upon the successful attainment of predetermined milestones for the Volixibat program. These payments are typically stipulated in collaboration or in-licensing agreements to reward progress in clinical trials or regulatory filings. Tracking these payments provides insight into the realized capital expenditure required to advance the asset toward market approval.
Ask your AI about Mirum Pharmaceuticals, Inc.'s volixibat — payments for achievement of various milestones.
Connect your AI assistant and compare it to peers, right in your chat.
